RWM
DNLI icon

Rialto Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Rialto Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181 Buy
7
+2
+40% +$41 ﹤0.01% 1858
2026
Q1 		$96 Sell
5
-3
-38% -$60 ﹤0.01% 1666
2025
Q4 		$133 Buy
8
+6
+300% +$101 ﹤0.01% 1593
2025
Q3 		$30 Hold
2
– – ﹤0.01% 1690
2025
Q2 		$28 Buy
+2
New +$28 ﹤0.01% 1672

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's DNLI Position: Q2 2026 in Review

Rialto Wealth Management increased its Denali Therapeutics (DNLI) stake by 40% in Q2 2026, buying an estimated $41 and bringing the position to 7 shares worth $181. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Rialto Wealth Management first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Rialto Wealth Management held 7 shares of Denali Therapeutics worth $181 as of Q2 2026.
  • Rialto Wealth Management bought 2 Denali Therapeutics shares in Q2 2026, an estimated $41.
  • Denali Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1858 holding.
  • Rialto Wealth Management first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.